Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734

POLICY TYPE  
Response to consultation

DATE  
2017-11-7

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE: Parliamentary submission
DATE: 2017-08-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE        2017-06-28
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE        2017-05-26
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation
DATE  2017-04-05
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada

https://policybase.cma.ca/link/policy10756

POLICY TYPE  Policy document
LAST REVIEWED  2017-03-04
DATE  2013-05-25
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada

https://policybase.cma.ca/link/policy13936

**POLICY TYPE**
Parliamentary submission

**DATE**
2016-10-18

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submissions
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Chair Statement - Application d’honneur

Graham, September 7, 2016 - The CMA’s submission to the Task Force on Marijuana’s consultation on legalizing and regulating marijuana is informed by the principles of patient safety and harm reduction put forward by the CMA in its comprehensive report, Dose: The Challenge of Safe Use, 2014. It is a summary of the feedback the CMA received from its members.

The CMA’s three main observations are based on the collective wisdom of its members and its expert knowledge of health and safety, and are consistent with the principles of harm reduction.

The first principle is the need for a controlled system of regulation and sale. A system that allows access to cannabis products only by the intended users, with proper safety procedures and controls, and which are transparent and accountable. This kind of system ensures safety and reduces the risk of harm and misuse.

The second principle is the importance of a comprehensive regulatory framework. A framework that includes the safety and quality of products, access for medicinal use, public health and safety, and public protection and policy-making.

The third principle is the need for a comprehensive information strategy. A strategy that includes education and awareness, and the provision of information that is accessible and reliable, and that is not misleading.

The CMA recommends that the principles of patient safety and harm reduction be followed in the development of the regulatory framework.

For information: health-canada.ca

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
National pharmacare in Canada: Getting there from here
https://policybase.cma.ca/link/policy11959

POLICY TYPE   Parliamentary submission
DATE          2016-06-01
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE Response to consultation
DATE 2016-03-19
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

**POLICY TYPE**
Response to consultation

**DATE**
2016-01-20

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

**Documents**
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE Response to consultation
DATE 2015-06-08
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Complementary and alternative medicine (update 2015)
https://policybase.cma.ca/link/policy11529

POLICY TYPE Policy document
DATE 2015-05-30
REPLACES Complementary and alternative medicine (Update 2008)
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Harms associated with opioids and other psychoactive prescription drugs
https://policybase.cma.ca/link/policy11535

POLICY TYPE
Policy document

DATE
2015-05-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11297

POLICY TYPE
Parliamentary submission

DATE
2014-10-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents